Preliminary safety data from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or oesophagogastric junction (OGJ) adenocarcinoma.

Bevacizumab in combination with oxaliplatin and doxorubicin or liposomal doxorubicin for hepatocellular cancer: A case series

“…A prior phase II trial in advanced sarcomas reported a 35% incidence of grade ≥2 cardiac toxicity 18 . However, the ongoing Perioperative Epirubicin Cisplatin plus Capecitabine with or without Bevacizumab trial in esophagogastric cancer (which combines bevacizumab with epirubicin) has not reported any safety concerns 19 . While none of the patients in this report underwent routine cardiac monitoring, none developed symptoms directly attributable to cardiac dysfunction.…”

Risk of Serious Neutropenic Events in Cancer Patients Treated with Bevacizumab: A Meta-analysis

“…After evaluating each remaining study, 22 RCTs were selected for the meta-analysis (Hurwitz et al, 2005;Sandler et al, 2006;Escudier et al, 2007;Herbst et al, 2007;Karrison et al, 2007;Miller et al, 2007;Allegra et al, 2009;Baar et al, 2009;Moehler et al, 2009;Reck et al, 2009;Robert et al, 2009;Van Cutsem et al, 2009;Brufsky et al, 2010;Burger et al, 2010;Kang et al, 2010;Kelly et al, 2010;Kindler et al, 2010;Miles et al, 2010;Okines et al, 2010;Rini et al, 2010;Tebbutt et al, 2010;Zalcman et al, 2010). The selection process is summarized in Figure 1.…”

Clinical trials in gastric cancer and the future

“…The current Medical Research Council phase II/III multicenter STO3 trial (ISRCTN 46020948) compares epirubicin, cisplatin and capecitabine (ECX), aquivalent to the ECF regime used in the MAGIC trial, to ECX plus bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, a regulator of angiogenesis. Favorable preliminary safety data for this combination were presented at the 2010 ASCO meeting 82. The primary endpoint is overall survival.…”